(NewsDirect)
Race Oncology Ltd(ASX:RAC) executive director Pete Smith speaks with Proactivealongside the company’s recently appointed CEO - 25-year veteran ofthe biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillettwill work closely with Dr Smith to steer the company's strategic,clinical and commercialisation efforts, with a primary focus onadvancing bisantrene. Dr Tillett is already well acquainted with thecancer-targeting biotech firm. From September 2019 to March 2023, heserved as Race's chief scientific officer and executive director,playing a crucial role in the company's growth and development.After this initial tenure, he continued to contribute to Race in aconsultancy capacity.
“My priority in stepping in as CEO is to ensure the clinicalstrategy we have for bisantrene is implemented and our promise toshareholders delivered. My belief in bisantrene and its commercialpotential has never wavered," Dr Tillett said. “We have anoutstanding team at Race to execute on these opportunities and make areal difference for both patients and shareholders."
ContactDetails
Proactive Investors
GreggCastano
+1 203-762-5649
Copyright (c) 2023 TheNewswire - All rights reserved.